Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Cariprazine in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have provided informed consent prior to any study specific procedures~* Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID)~* Patients with normal physical examination, laboratory, vital signs,and/ or electrocardiogram (ECG)~* Current psychotic episode (schizophrenia exacerbation) \< 2 weeks duration at Visit 1~* Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCIPANSS) total score ≥ 80 and ≤ 120~* CGI-S score ≥ 4~Exclusion Criteria:~* Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders~* Bipolar I and II disorder~* Pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and other cognitive disorders~* DSM-IV-TR axis II disorder of sufficient severity to interfere with participation in this study~* Women who are pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cariprazine 3mg (Type: EXPERIMENTAL): Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
- Cariprazine 6mg (Type: EXPERIMENTAL): Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
- Aripiprazole 10mg (Type: ACTIVE_COMPARATOR): Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
- Placebo (Type: PLACEBO_COMPARATOR): Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).